News & Media

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Torqur AG Presents Interim Phase 2 Clinical Trial Results at American Academy of Dermatology

Spotlight on Leadership: Dr. Vladimir Cmiljanovic in The CEO Magazine

Rocketvax and HALIX Collaborate to Advance the VIRUFLEX(TM) Platform and Next-Generation Nasal COVID-19 Vaccine

Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)

Promising Next-Generation SARS-CoV-2 Live Vaccine Demonstrates Remarkable Safety, Protection, and Immunity Profile in Pre-Clinical Studies

Rocketvax Announces Collaboration with the US National Institutes of Health (NIH) for Clinical Trial of Nasal, Live-Attenuated NextGen SARS-CoV-2 Vaccine

Torqur AG Announces First Patient Dosed in Phase 2 Clinical Trial of Bimiralisib in Actinic Keratosis

Swiss Biotech TORQUR AG Unveils Groundbreaking Data on New Cancer Drug Candidate Bimiralisib

New study on the benefits of COVID-19 nasal spray vaccination published in "Nature Communications"

Renowned Venture Capitalist and Angel Investor Daniel Gutenberg Joins Swiss Rockets AG’s Board of Directors and Invests in Promising Biotech Startups

Rocketvax AG selected to participate in SIX Swiss Exchange Sparks IPO Academy

Swiss Rockets AG and its subsidiary Torqur AG welcome four key scientific members

Swiss Rockets AG further advances its technologies in cooperation with Serbia

Nasal vaccine against coronavirus further improved